

Evan T Keller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6028855/evan-t-keller-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

240
papers

19,587
citations

69
h-index

135
g-index

281
ext. papers

22,855
ext. citations

6.3
avg, IF

6.35
L-index

#	Paper	IF	Citations
240	A Bioreactor for 3D Modeling of the Mechanical Stimulation of Osteocytes.. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022 , 10, 797542	5.8	
239	Differential immune landscapes in appendicular versus axial skeleton.. <i>PLoS ONE</i> , 2022 , 17, e0267642	3.7	
238	Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 1623	10.1	1
237	Cigarette smoke-associated inflammation impairs bone remodeling through NFB activation. <i>Journal of Translational Medicine</i> , 2021 , 19, 163	8.5	1
236	IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. <i>JCI Insight</i> , 2021 , 6,	9.9	7
235	An infection-induced RhoB-Beclin 1-Hsp90 complex enhances clearance of uropathogenic Escherichia coli. <i>Nature Communications</i> , 2021 , 12, 2587	17.4	2
234	Effects of Analgesics on Tumor Growth in Mouse Models of Prostate Cancer Bone Metastasis. <i>Journal of the American Association for Laboratory Animal Science</i> , 2021 , 60, 341-348	1.3	
233	SEducatedSOsteoblasts Reduce Osteoclastogenesis in a Bone-Tumor Mimetic Microenvironment. <i>Cancers</i> , 2021 , 13,	6.6	1
232	Extracellular Vesicles and Bone-Associated Cancer. <i>Current Osteoporosis Reports</i> , 2021 , 19, 223-229	5.4	1
231	Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer. <i>BMC Cancer</i> , 2021 , 21, 1316	4.8	2
230	Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2020 , 18, 1290-1301	6.6	8
229	Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 676-685	6.8	16
228	Integrative differential expression and gene set enrichment analysis using summary statistics for scRNA-seq studies. <i>Nature Communications</i> , 2020 , 11, 1585	17.4	10
227	Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	35
226	Photoacoustic spectral analysis at ultraviolet wavelengths for characterizing the Gleason grades of prostate cancer. <i>Optics Letters</i> , 2020 , 45, 6042-6045	3	3
225	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 332-339.e2	3.3	1
224	Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC. <i>Advanced Biology</i> , 2020 , 4, e2000110	3.5	5

223	Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells. <i>Biomedicines</i> , 2020 , 8,	4.8	14
222	Multiple Roles of Osteocytes in Bone-Associated Cancers 2020 , 219-224		
221	Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. <i>Oncogene</i> , 2020 , 39, 204-218	9.2	16
220	Cytotoxic necrotizing factor 1 promotes bladder cancer angiogenesis through activating RhoC. <i>FASEB Journal</i> , 2020 , 34, 7927-7940	0.9	6
219	SNV identification from single-cell RNA sequencing data. <i>Human Molecular Genetics</i> , 2019 , 28, 3569-3583	3.6	13
218	Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2883-2899	16.6	74
217	A surgical orthotopic approach for studying the invasive progression of human bladder cancer. <i>Nature Protocols</i> , 2019 , 14, 738-755	18.8	10
216	Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1999-2012	4.9	18
215	Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression. <i>Journal of Cellular Biochemistry</i> , 2019 , 120, 16946-16955	4.7	3
214	Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA. <i>Molecular Carcinogenesis</i> , 2019 , 58, 1886-1896	5	12
213	Macrofluidic recirculating model of skeletal metastasis. <i>Scientific Reports</i> , 2019 , 9, 14979	4.9	1
212	Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. <i>Oncogene</i> , 2019 , 38, 4540-4559	9.2	40
211	Mindful exercise versus non-mindful exercise for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. <i>Complementary Therapies in Clinical Practice</i> , 2018 , 32, 17-24	3.5	15
210	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. <i>European Urology</i> , 2018 , 74, 741-753	10.2	43
209	Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. <i>Cancer Letters</i> , 2018 , 436, 96-108	9.9	6
208	The Use of Mature Zebrafish (<i>Danio rerio</i>) as a Model for Human Aging and Disease 2018 , 351-359		5
207	Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. <i>Journal of Clinical Investigation</i> , 2018 , 128, 248-266	15.9	62
206	Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway. <i>Oncotarget</i> , 2018 , 9, 9206-9218	3.3	13

205	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. <i>Oncotarget</i> , 2018 , 9, 16185-16196	3.3	18
204	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. <i>Anticancer Research</i> , 2018 , 38, 2045-2055	2.3	3
203	Prostate cancer tends to metastasize in the bone-mimicking microenvironment via activating NF- κ B signaling. <i>Journal of Biomedical Research</i> , 2018 , 32, 343-353	1.5	3
202	Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. <i>Calcified Tissue International</i> , 2018 , 102, 152-162	3.9	20
201	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018 , 7, 1535750	16.4	3642
200	Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3 β signaling. <i>Scientific Reports</i> , 2017 , 7, 41656	4.9	35
199	Metformin targets multiple signaling pathways in cancer. <i>Chinese Journal of Cancer</i> , 2017 , 36, 17		70
198	Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. <i>Molecular Cancer Research</i> , 2017 , 15, 457-466	6.6	8
197	Fibulin-3 promotes muscle-invasive bladder cancer. <i>Oncogene</i> , 2017 , 36, 5243-5251	9.2	28
196	Abituzumab Targeting of α V-Class Integrins Inhibits Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2017 , 15, 875-883	6.6	21
195	Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. <i>Chinese Journal of Cancer</i> , 2017 , 36, 35		36
194	Immune mediators in the tumor microenvironment of prostate cancer. <i>Chinese Journal of Cancer</i> , 2017 , 36, 29		25
193	An integrative model of prostate cancer interaction with the bone microenvironment. <i>Mathematical Biosciences</i> , 2017 , 294, 1-14	3.9	16
192	High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells. <i>Cell Systems</i> , 2017 , 5, 295-304.e4	10.6	61
191	Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42-PAK1 axis. <i>Journal of Pathology</i> , 2017 , 243, 208-219	9.4	20
190	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. <i>Cancer Research</i> , 2017 , 77, 74-85	10.1	100
189	Analysis of Integrin Alpha2Beta1 (α 2 β 1) Expression as a Biomarker of Skeletal Metastasis. <i>Biomarkers in Disease</i> , 2017 , 487-506		3
188	Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. <i>Oncogene</i> , 2016 , 35, 366-76	9.2	48

187	Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 87-95	4.4	29
186	Providing prostate cancer survivorship care in Japan: Implications from the USA care model. <i>International Journal of Urology</i> , 2016 , 23, 906-915	2.3	2
185	Exosome-derived microRNAs contribute to prostate cancer chemoresistance. <i>International Journal of Oncology</i> , 2016 , 49, 838-46	4.4	56
184	Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion. <i>Osteoporosis International</i> , 2016 , 27, 1469-1476	5.3	46
183	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016 , 18, 1-9	6.4	19
182	IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker. <i>Oncotarget</i> , 2016 , 7, 68140-68150	3.3	8
181	Analysis of Integrin Alpha2Beta1 ($\alpha 2 \beta 1$) Expression as a Biomarker of Skeletal Metastasis. <i>Exposure and Health</i> , 2016 , 1-20	8.8	
180	Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis. <i>Journal of Cancer</i> , 2016 , 7, 192-9	4.5	23
179	Skp2 is associated with paclitaxel resistance in prostate cancer cells. <i>Oncology Reports</i> , 2016 , 36, 559-66	3.5	25
178	Raman microscopy of bladder cancer cells expressing green fluorescent protein. <i>Journal of Biomedical Optics</i> , 2016 , 21, 115001	3.5	5
177	Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation. <i>Nature Cell Biology</i> , 2016 , 18, 917-29	23.4	126
176	Notch Pathway Inhibition Using PF-03084014, a β -Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4619-29	12.9	60
175	Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. <i>Cancer Research</i> , 2015 , 75, 2151-8	10.1	100
174	Wnt3a: functions and implications in cancer. <i>Chinese Journal of Cancer</i> , 2015 , 34, 554-62		46
173	Micro/Nanostructures and Mechanical Properties of Trabecular Bone in Ovariectomized Rats. <i>International Journal of Endocrinology</i> , 2015 , 2015, 252503	2.7	9
172	Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. <i>Molecular Cancer Research</i> , 2015 , 13, 197-207	6.6	31
171	Translational progress on tumor biomarkers. <i>Thoracic Cancer</i> , 2015 , 6, 665-71	3.2	9
170	Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer. <i>Prostate</i> , 2015 , 75, 292-302	4.2	13

169	Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2015 , 20, 407-17	1.3	10
168	Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. <i>Clinical Cancer Research</i> , 2014 , 20, 617-30	12.9	69
167	Recent advances in bone-targeted therapies of metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2014 , 40, 730-8	14.4	44
166	Review of Animal Models of Prostate Cancer Bone Metastasis. <i>Veterinary Sciences</i> , 2014 , 1, 16-39	2.4	16
165	Mangiferin attenuates TH1/TH2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. <i>PLoS ONE</i> , 2014 , 9, e100394	3.7	45
164	A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. <i>Journal of Hepatocellular Carcinoma</i> , 2014 , 1, 1-7	5.3	7
163	Targeting the Notch signaling pathway in cancer therapeutics. <i>Thoracic Cancer</i> , 2014 , 5, 473-86	3.2	28
162	Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of E-catenin activation of the DKK1 promoter in prostate cancer. <i>Oncogene</i> , 2014 , 33, 2464-77	9.2	15
161	Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF Factor 8 (MFG-E8)-mediated efferocytosis. <i>Journal of Biological Chemistry</i> , 2014 , 289, 24560-72	5.4	106
160	Osteocytes serve as a progenitor cell of osteosarcoma. <i>Journal of Cellular Biochemistry</i> , 2014 , 115, 1420-7	4.7	28
159	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 692-701	6.4	78
158	Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types. <i>Critical Reviews in Oncogenesis</i> , 2014 , 19, 455-68	1.3	31
157	Extracellular vesicle-mediated reversal of taxane resistance and the malignant phenotype in prostate cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16028-e16028	2.2	
156	SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation. <i>Anticancer Research</i> , 2014 , 34, 2821-31	2.3	20
155	Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin $\beta 1$. <i>Prostate</i> , 2013 , 73, 1159-70	4.2	26
154	Integrin alpha2beta 1 ($\alpha 2 \beta 1$) promotes prostate cancer skeletal metastasis. <i>Clinical and Experimental Metastasis</i> , 2013 , 30, 569-78	4.7	71
153	Activation of the Wnt pathway through AR79, a GSK3 β inhibitor, promotes prostate cancer growth in soft tissue and bone. <i>Molecular Cancer Research</i> , 2013 , 11, 1597-610	6.6	27
152	A novel canine model for prostate cancer. <i>Prostate</i> , 2013 , 73, 952-9	4.2	27

151	Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. <i>Nature Communications</i> , 2013 , 4, 1795	17.4	269
150	MT1-MMP-dependent control of skeletal stem cell commitment via a β -integrin/YAP/TAZ signaling axis. <i>Developmental Cell</i> , 2013 , 25, 402-16	10.2	185
149	Stromal cells in tumor microenvironment and breast cancer. <i>Cancer and Metastasis Reviews</i> , 2013 , 32, 303-15	9.6	438
148	Mechanisms of Metastatic Tumor Dormancy. <i>Journal of Clinical Medicine</i> , 2013 , 2, 136-50	5.1	24
147	Understanding and targeting osteoclastic activity in prostate cancer bone metastases. <i>Current Molecular Medicine</i> , 2013 , 13, 626-39	2.5	46
146	Detection and isolation of human disseminated tumor cells in the murine bone marrow stem cell niche. <i>Methods in Molecular Biology</i> , 2013 , 1035, 207-15	1.4	2
145	SPDEF: a molecular switch for E-cadherin expression that promotes prostate cancer metastasis. <i>Asian Journal of Andrology</i> , 2013 , 15, 584-5	2.8	4
144	Evaluation of a novel irreversible pan-HER inhibitor in bladder cancer models.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 253-253	2.2	
143	Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2Shydroxyflavanone. <i>Anticancer Research</i> , 2013 , 33, 4453-61	2.3	8
142	Wnt and Wnt inhibitors in bone metastasis. <i>BoneKEy Reports</i> , 2012 , 1, 101		22
141	Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. <i>Journal of Urology</i> , 2012 , 188, 1957-64	2.5	33
140	Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. <i>Neoplasia</i> , 2012 , 14, 429-39	6.4	47
139	Raf kinase inhibitor protein (RKIP) in cancer. <i>Cancer and Metastasis Reviews</i> , 2012 , 31, 615-20	9.6	66
138	Prostate cancer and parasitism of the bone hematopoietic stem cell niche. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2012 , 22, 131-48	1.3	21
137	Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer. <i>Prostate</i> , 2012 , 72, 1789-801	4.2	18
136	Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. <i>Cancer Research</i> , 2012 , 72, 3091-104	10.1	171
135	Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. <i>Molecular Cancer Research</i> , 2012 , 10, 282-92	6.6	37
134	Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. <i>Oncolmmunology</i> , 2012 , 1, 152-161	7.2	97

133	Transcriptional regulation of RKIP expression by androgen in prostate cells. <i>Cellular Physiology and Biochemistry</i> , 2012 , 30, 1340-50	3.9	24
132	Raman spectroscopy of bone metastasis 2012 ,		2
131	Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 265-265	2.2	7
130	ERK5 signalling in prostate cancer promotes an invasive phenotype. <i>British Journal of Cancer</i> , 2011 , 104, 664-72	8.7	66
129	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011 , 29, 1432-40	4.3	44
128	The PCa Tumor Microenvironment. <i>Cancer Microenvironment</i> , 2011 , 4, 283-97	6.1	21
127	Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. <i>Prostate</i> , 2011 , 71, 615-25	4.2	86
126	Development of a brain metastatic canine prostate cancer cell line. <i>Prostate</i> , 2011 , 71, 1251-63	4.2	28
125	Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. <i>Clinical Cancer Research</i> , 2011 , 17, 3112-22	12.9	24
124	Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. <i>Journal of Clinical Investigation</i> , 2011 , 121, 3206-19	15.9	246
123	Prostate cancer cells metastasize to the hematopoietic stem cell niche in bone. <i>Asian Journal of Andrology</i> , 2011 , 13, 622-3	2.8	2
122	Role of Raf Kinase Inhibitor Protein in Pathophysiology of Prostate Cancer. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2011 , 2, 89-94		6
121	ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. <i>In Vivo</i> , 2011 , 25, 69-76	2.3	40
120	Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. <i>Oncogene</i> , 2010 , 29, 811-21	9.2	211
119	Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. <i>Cancer Research</i> , 2010 , 70, 5014-23	10.1	18
118	p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. <i>Cancer Research</i> , 2010 , 70, 9916-26	10.1	32
117	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. <i>Prostate</i> , 2010 , 70, 48-60	4.2	23
116	Pathophysiology of Prostate Cancer Bone Metastasis 2010 , 245-254		

115	Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. <i>Journal of Interferon and Cytokine Research</i> , 2009 , 29, 105-12	3.5	19
114	Expression of PGK1 by prostate cancer cells induces bone formation. <i>Molecular Cancer Research</i> , 2009 , 7, 1595-604	6.6	21
113	Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. <i>Endocrine-Related Cancer</i> , 2009 , 16, 1139-55	5.7	50
112	EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. <i>Prostate</i> , 2009 , 69, 528-37	4.2	33
111	Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. <i>Prostate</i> , 2009 , 69, 1222-34	4.2	40
110	A bioluminescent orthotopic mouse model of human osteosarcoma that allows sensitive and rapid evaluation of new therapeutic agents In vivo. <i>In Vivo</i> , 2009 , 23, 661-8	2.3	14
109	Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. <i>Oncogene</i> , 2008 , 27, 2243-8	9.2	158
108	Heat stress-induced heat shock protein 70 expression is dependent on ERK activation in zebrafish (<i>Danio rerio</i>) cells. <i>Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology</i> , 2008 , 150, 307-14	2.6	38
107	Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. <i>Neoplasia</i> , 2008 , 10, 797-803	6.4	91
106	Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. <i>Bone</i> , 2008 , 42, 806-18	4.7	96
105	An in vivo mouse model for human prostate cancer metastasis. <i>Neoplasia</i> , 2008 , 10, 371-80	6.4	64
104	Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. <i>Cancer Research</i> , 2008 , 68, 9663-70	10.1	80
103	Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. <i>Cancer Research</i> , 2008 , 68, 5785-94	10.1	117
102	RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. <i>Prostate</i> , 2008 , 68, 92-104	4.2	148
101	RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. <i>Prostate</i> , 2008 , 68, 820-9	4.2	25
100	Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. <i>Prostate</i> , 2008 , 68, 1396-404	4.2	110
99	Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. <i>International Journal of Cancer</i> , 2008 , 123, 1034-42	7.5	92
98	Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 153-60	4	46

97	Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. <i>Journal of Immunology</i> , 2007 , 179, 1423-6	5.3	143
96	Biology and Therapeutic Basis of Prostate Cancer Bone Metastasis 2007 , 175-191		
95	PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. <i>International Journal of Cancer</i> , 2007 , 121, 724-33	7.5	55
94	CCR2 expression correlates with prostate cancer progression. <i>Journal of Cellular Biochemistry</i> , 2007 , 101, 676-85	4.7	100
93	New trends in the treatment of bone metastasis. <i>Journal of Cellular Biochemistry</i> , 2007 , 102, 1095-102	4.7	18
92	The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. <i>Prostate</i> , 2007 , 67, 955-67	4.2	106
91	Efficient mapping of mendelian traits in dogs through genome-wide association. <i>Nature Genetics</i> , 2007 , 39, 1321-8	36.3	398
90	NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. <i>Nature Medicine</i> , 2007 , 13, 62-9	50.5	262
89	Expression of the cytoskeleton linker protein ezrin in human cancers. <i>Clinical and Experimental Metastasis</i> , 2007 , 24, 69-78	4.7	102
88	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. <i>American Journal of Physiology - Cell Physiology</i> , 2007 , 292, C987-95	5.4	251
87	Why should we still care about oncogenes?. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 418-27	6.1	12
86	A glycolytic mechanism regulating an angiogenic switch in prostate cancer. <i>Cancer Research</i> , 2007 , 67, 149-59	10.1	127
85	Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. <i>Cancer Research</i> , 2007 , 67, 3646-53	10.1	148
84	The role of Wnts in bone metastases. <i>Cancer and Metastasis Reviews</i> , 2006 , 25, 551-8	9.6	64
83	Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. <i>Clinical Genitourinary Cancer</i> , 2006 , 4, 299-302	3.3	63
82	Role of Wnts in prostate cancer bone metastases. <i>Journal of Cellular Biochemistry</i> , 2006 , 97, 661-72	4.7	134
81	Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. <i>Cancer Research</i> , 2006 , 66, 3087-95	10.1	125
80	Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. <i>Cancer Research</i> , 2006 , 66, 8648-54	10.1	104

79	Issues of aging and geriatric medicine: relevance to cancer treatment and hematopoietic reconstitution. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 100-6	4.7	6
78	The Use of Mature Zebrafish (<i>Danio rerio</i>) as a Model for Human Aging and Disease 2006 , 309-316		1
77	Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. <i>Prostate</i> , 2006 , 66, 248-56	4.2	167
76	Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. <i>International Journal of Urology</i> , 2006 , 13, 593-600	2.3	19
75	Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 318-29	6.3	306
74	The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. <i>Cancer Research</i> , 2005 , 65, 8818-25	10.1	59
73	The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. <i>Journal of Cellular Biochemistry</i> , 2005 , 94, 273-8	4.7	76
72	Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. <i>Prostate Cancer and Prostatic Diseases</i> , 2005 , 8, 253-9	6.2	25
71	Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8232-41	2.2	121
70	Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. <i>Cancer Research</i> , 2005 , 65, 10921-9	10.1	81
69	Prostate cancer cells promote osteoblastic bone metastases through Wnts. <i>Cancer Research</i> , 2005 , 65, 7554-60	10.1	250
68	Bone turnover mediates preferential localization of prostate cancer in the skeleton. <i>Endocrinology</i> , 2005 , 146, 1727-36	4.8	156
67	Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. <i>Cancer Research</i> , 2005 , 65, 8274-85	10.1	164
66	The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. <i>Cancer Research</i> , 2004 , 64, 765-71	10.1	154
65	Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. <i>Journal of Biological Chemistry</i> , 2004 , 279, 29121-9	5.4	59
64	RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. <i>Journal of Biological Chemistry</i> , 2004 , 279, 17515-23	5.4	180
63	Mechanisms of unexplained anemia in the nursing home. <i>Journal of the American Geriatrics Society</i> , 2004 , 52, 423-7	5.6	88
62	Alzheimer's Abeta vaccination of rhesus monkeys (<i>Macaca mulatta</i>). <i>Mechanisms of Ageing and Development</i> , 2004 , 125, 149-51	5.6	22

61	In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. <i>Experimental Gerontology</i> , 2004 , 39, 239-47	4.5	29
60	The role of Raf kinase inhibitor protein (RKIP) in health and disease. <i>Biochemical Pharmacology</i> , 2004 , 68, 1049-53	6	136
59	The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. <i>Clinical and Experimental Metastasis</i> , 2004 , 21, 381-7	4.7	46
58	Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. <i>Clinical and Experimental Metastasis</i> , 2004 , 21, 399-408	4.7	45
57	In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. <i>Prostate</i> , 2004 , 59, 360-9	4.2	38
56	Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. <i>Journal of Cellular Biochemistry</i> , 2004 , 91, 718-29	4.7	208
55	Detection and isolation of circulating tumor cells in urologic cancers: a review. <i>Neoplasia</i> , 2004 , 6, 302-9	6.4	49
54	The use of mature zebrafish (<i>Danio rerio</i>) as a model for human aging and disease. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2004 , 138, 335-41	3.2	69
53	Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. <i>Cancer Letters</i> , 2004 , 207, 131-7	9.9	68
52	Zebrafish, killifish, neither fish, both fish?. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2004 , 59, B873-5	6.4	2
51	Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. <i>Cancer Research</i> , 2004 , 64, 994-9	10.1	128
50	Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). <i>Anti-Cancer Drugs</i> , 2004 , 15, 663-9	2.4	46
49	Alzheimer A beta vaccination of rhesus monkeys (<i>Macaca mulatta</i>). <i>Alzheimer Disease and Associated Disorders</i> , 2004 , 18, 44-6	2.5	20
48	Opg, RANKL, and RANK in cancer metastasis: expression and regulation. <i>Cancer Treatment and Research</i> , 2004 , 118, 149-72	3.5	27
47	Characterization of C4-2 prostate cancer bone metastases and their response to castration. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1882-8	6.3	32
46	Separation of retinoid-induced epidermal and dermal thickening from skin irritation. <i>Archives of Dermatological Research</i> , 2003 , 295, 255-62	3.3	25
45	Characterization of the heat shock response in mature zebrafish (<i>Danio rerio</i>). <i>Experimental Gerontology</i> , 2003 , 38, 683-91	4.5	56
44	Stromal factors involved in prostate carcinoma metastasis to bone. <i>Cancer</i> , 2003 , 97, 739-47	6.4	158

43	The comparative biology of skeletal metastasis. <i>Veterinary and Comparative Oncology</i> , 2003 , 1, 131-9	2.5	2
42	Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 878-89	9.7	321
41	Hematologic and serum biochemical values for zebrafish (<i>Danio rerio</i>). <i>Comparative Medicine</i> , 2003 , 53, 37-41	1.6	38
40	Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. <i>Cancer Research</i> , 2003 , 63, 7883-90	10.1	105
39	Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone 2002 , 197-213		
38	Trends in early mineralization of murine calvarial osteoblastic cultures: a Raman microscopic study. <i>Journal of Raman Spectroscopy</i> , 2002 , 33, 536-543	2.3	48
37	Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. <i>Prostate</i> , 2002 , 51, 10-20	4.2	34
36	Cyclooxygenase-2 promotes prostate cancer progression. <i>Prostate</i> , 2002 , 53, 232-40	4.2	126
35	Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 1256-63	6.3	17
34	20 Immunohistochemical expression of raf kinase inhibitor protein in prostate carcinoma. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2002 , 471-479		
33	Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. <i>Endocrinology</i> , 2002 , 143, 4038-47	4.8	104
32	Early mineralization of normal and pathologic calvaria as revealed by Raman spectroscopy 2002 ,		10
31	The role of osteoclastic activity in prostate cancer skeletal metastases. <i>Drugs of Today</i> , 2002 , 38, 91-102		40
30	Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. <i>Cancer Research</i> , 2002 , 62, 1832-7	10.1	689
29	Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. <i>Prostate</i> , 2001 , 48, 47-53	4.2	108
28	Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. <i>Prostate</i> , 2001 , 46, 319-26	4.2	17
27	Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. <i>Cancer and Metastasis Reviews</i> , 2001 , 20, 333-49	9.6	150
26	The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (<i>Macaca mulatta</i>) model of menopause. <i>Journal of Reproductive Immunology</i> , 2001 , 50, 41-55	4.2	42

25	Hydrogen peroxide activates NFkappaB and the interleukin-6 promoter through NFkappaB-inducing kinase. <i>Antioxidants and Redox Signaling</i> , 2001 , 3, 493-504	8.4	98
24	Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. <i>American Journal of Pathology</i> , 2001 , 158, 2219-28	5.8	50
23	Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. <i>Prostate</i> , 2001 , 47, 212-21	4.2	137
22	Ethanol activates NFkappaB DNA binding and p56lck protein tyrosine kinase in human osteoblast-like cells. <i>Bone</i> , 2001 , 28, 167-73	4.7	24
21	Interleukin-6 and prostate cancer progression. <i>Cytokine and Growth Factor Reviews</i> , 2001 , 12, 33-40	17.9	213
20	Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. <i>Journal of Clinical Investigation</i> , 2001 , 107, 1235-44	15.9	364
19	Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice 2001 , 48, 47		2
18	Neurotrophic role of interleukin-6 and soluble interleukin-6 receptors in N1E-115 neuroblastoma cells. <i>Journal of Neuroimmunology</i> , 2000 , 102, 8-16	3.5	18
17	Ovariectomy does not induce osteopenia through interleukin-6 in rhesus monkeys (Macaca mulatta). <i>Bone</i> , 2000 , 26, 55-62	4.7	12
16	Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle. <i>Bone</i> , 2000 , 26, 79-85	4.7	35
15	TUMOR NECROSIS FACTOR- RE PRESESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINE. <i>Journal of Urology</i> , 2000 , 164, 800-805	2.5	69
14	Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. <i>Annual Review of Medicine</i> , 2000 , 51, 245-70	17.4	921
13	Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. <i>Journal of Clinical Investigation</i> , 2000 , 106, 887-95	15.9	102
12	Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. <i>Journal of Urology</i> , 2000 , 164, 800-5	2.5	37
11	Correlation of serum L-carnitine and dehydro-epiandrosterone sulphate levels with age and sex in healthy adults. <i>Age and Ageing</i> , 1999 , 28, 211-6	3	16
10	Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. <i>Calcified Tissue International</i> , 1999 , 64, 527-33	3.9	30
9	Orchiectomy increases bone marrow interleukin-6 levels in mice. <i>Calcified Tissue International</i> , 1998 , 62, 219-26	3.9	40
8	Estrogen inhibits phorbol ester-induced I kappa B alpha transcription and protein degradation. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 244, 691-5	3.4	71

7	Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. <i>Human Gene Therapy</i> , 1998 , 9, 1851-61	4.8	50
6	Immunologic aspects of osteoporosis. <i>Developmental and Comparative Immunology</i> , 1997 , 21, 487-99	3.2	56
5	Inhibition of NFkappaB activity through maintenance of IkappaBalph levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. <i>Journal of Biological Chemistry</i> , 1996 , 271, 26267-75	5.4	106
4	Androgen receptor: an overview. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 1995 , 5, 97-125	1.3	221
3	Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. <i>Journal of Drug Targeting</i> , 1994 , 2, 391-6	5.4	31
2	Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 1993 , 7, 289-95	3.1	158
1	Immune-mediated disease as a risk factor for canine lymphoma. <i>Cancer</i> , 1992 , 70, 2334-7	6.4	30